Protein kinase C ε translocation and phosphorylation by cis- diamminedichloroplatinum(II) (CDDP)

Potential role in CDDP-mediated cytotoxicity

Tohru Ohmori, Carlos L. Arteaga

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Phorbol ester-like protein kinase C (PKC) activators, such as 12-O- tetradecanoylphorbol-13-acetate, and perturbation of some growth factor receptors have been reported to alter the cytotoxicity of cisdiamminedichloroplatinum(II) (CDDP). To study the mechanism of this alteration, we have examined the effect of CDDP per se on PKC isozymes. The SKBR-3 human breast carcinoma cell line exhibits at least six different PKC isozymes (PKC α, βI, βII, δ, ε, and ζ). After exposure to 10-100 μM CDDP for 3 h, only PKC ε translocated from the plasma membrane to the nuclear membrane and to the cytosolic fraction. This translocation was observed in a time- and dose-dependent manner by Western blot and confocal microscopy. CDDP also decreased the mobility of PKC ε in the nuclear membrane fraction, an effect that was blocked by protein phosphatase 2A, suggesting drug-mediated isozyme phosphorylation. This translocation and phosphorylation were also induced by the cisplatin analogue carboplatin but not with the anticancer agents Adriamycin and Taxol. Antisense oligodeoxynucleotides against PKC ε down-regulated isozyme content, blocked drug-induced translocation, and reduced cisplatin-mediated cytotoxicity 3- fold compared to that of sense-treated cells. Antisense PKC ε also decreased SKBR-3 cell sensitivity to carboplatin but not to Adriamycin and Taxol. These data support a role for PKC ε translocation and phosphorylation on CDDP- mediated toxicity.

Original languageEnglish (US)
Pages (from-to)345-353
Number of pages9
JournalCell Growth and Differentiation
Volume9
Issue number4
StatePublished - Jan 1 1998

Fingerprint

Protein Kinase C
Cisplatin
Phosphorylation
Isoenzymes
Carboplatin
Nuclear Envelope
Paclitaxel
Doxorubicin
Protein Phosphatase 2
Growth Factor Receptors
Oligodeoxyribonucleotides
Phorbol Esters
Tetradecanoylphorbol Acetate
Confocal Microscopy
Pharmaceutical Preparations
Antineoplastic Agents
Western Blotting
Cell Membrane
Breast Neoplasms
Cell Line

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

@article{7726f97ae6204355b594c071d201f17c,
title = "Protein kinase C ε translocation and phosphorylation by cis- diamminedichloroplatinum(II) (CDDP): Potential role in CDDP-mediated cytotoxicity",
abstract = "Phorbol ester-like protein kinase C (PKC) activators, such as 12-O- tetradecanoylphorbol-13-acetate, and perturbation of some growth factor receptors have been reported to alter the cytotoxicity of cisdiamminedichloroplatinum(II) (CDDP). To study the mechanism of this alteration, we have examined the effect of CDDP per se on PKC isozymes. The SKBR-3 human breast carcinoma cell line exhibits at least six different PKC isozymes (PKC α, βI, βII, δ, ε, and ζ). After exposure to 10-100 μM CDDP for 3 h, only PKC ε translocated from the plasma membrane to the nuclear membrane and to the cytosolic fraction. This translocation was observed in a time- and dose-dependent manner by Western blot and confocal microscopy. CDDP also decreased the mobility of PKC ε in the nuclear membrane fraction, an effect that was blocked by protein phosphatase 2A, suggesting drug-mediated isozyme phosphorylation. This translocation and phosphorylation were also induced by the cisplatin analogue carboplatin but not with the anticancer agents Adriamycin and Taxol. Antisense oligodeoxynucleotides against PKC ε down-regulated isozyme content, blocked drug-induced translocation, and reduced cisplatin-mediated cytotoxicity 3- fold compared to that of sense-treated cells. Antisense PKC ε also decreased SKBR-3 cell sensitivity to carboplatin but not to Adriamycin and Taxol. These data support a role for PKC ε translocation and phosphorylation on CDDP- mediated toxicity.",
author = "Tohru Ohmori and Arteaga, {Carlos L.}",
year = "1998",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "345--353",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Protein kinase C ε translocation and phosphorylation by cis- diamminedichloroplatinum(II) (CDDP)

T2 - Potential role in CDDP-mediated cytotoxicity

AU - Ohmori, Tohru

AU - Arteaga, Carlos L.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Phorbol ester-like protein kinase C (PKC) activators, such as 12-O- tetradecanoylphorbol-13-acetate, and perturbation of some growth factor receptors have been reported to alter the cytotoxicity of cisdiamminedichloroplatinum(II) (CDDP). To study the mechanism of this alteration, we have examined the effect of CDDP per se on PKC isozymes. The SKBR-3 human breast carcinoma cell line exhibits at least six different PKC isozymes (PKC α, βI, βII, δ, ε, and ζ). After exposure to 10-100 μM CDDP for 3 h, only PKC ε translocated from the plasma membrane to the nuclear membrane and to the cytosolic fraction. This translocation was observed in a time- and dose-dependent manner by Western blot and confocal microscopy. CDDP also decreased the mobility of PKC ε in the nuclear membrane fraction, an effect that was blocked by protein phosphatase 2A, suggesting drug-mediated isozyme phosphorylation. This translocation and phosphorylation were also induced by the cisplatin analogue carboplatin but not with the anticancer agents Adriamycin and Taxol. Antisense oligodeoxynucleotides against PKC ε down-regulated isozyme content, blocked drug-induced translocation, and reduced cisplatin-mediated cytotoxicity 3- fold compared to that of sense-treated cells. Antisense PKC ε also decreased SKBR-3 cell sensitivity to carboplatin but not to Adriamycin and Taxol. These data support a role for PKC ε translocation and phosphorylation on CDDP- mediated toxicity.

AB - Phorbol ester-like protein kinase C (PKC) activators, such as 12-O- tetradecanoylphorbol-13-acetate, and perturbation of some growth factor receptors have been reported to alter the cytotoxicity of cisdiamminedichloroplatinum(II) (CDDP). To study the mechanism of this alteration, we have examined the effect of CDDP per se on PKC isozymes. The SKBR-3 human breast carcinoma cell line exhibits at least six different PKC isozymes (PKC α, βI, βII, δ, ε, and ζ). After exposure to 10-100 μM CDDP for 3 h, only PKC ε translocated from the plasma membrane to the nuclear membrane and to the cytosolic fraction. This translocation was observed in a time- and dose-dependent manner by Western blot and confocal microscopy. CDDP also decreased the mobility of PKC ε in the nuclear membrane fraction, an effect that was blocked by protein phosphatase 2A, suggesting drug-mediated isozyme phosphorylation. This translocation and phosphorylation were also induced by the cisplatin analogue carboplatin but not with the anticancer agents Adriamycin and Taxol. Antisense oligodeoxynucleotides against PKC ε down-regulated isozyme content, blocked drug-induced translocation, and reduced cisplatin-mediated cytotoxicity 3- fold compared to that of sense-treated cells. Antisense PKC ε also decreased SKBR-3 cell sensitivity to carboplatin but not to Adriamycin and Taxol. These data support a role for PKC ε translocation and phosphorylation on CDDP- mediated toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0031843617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031843617&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 345

EP - 353

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 4

ER -